KonstantinHristovDragnevMD

Hematologic Oncology, Thoracic Cancer

Professor of Medicine, Geisel School of Medicine at Dartmouth, Associate Director for Clinical Research, Norris Cotton Cancer Center

Join to view full profile

Dr. Dragnev is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Dragnev's full profile

Already have an account?

Office
1 Medical Center Dr
Lebanon, NH 03756
Phone+1 603-650-6345

Fax+1 603-650-9496
Is this information wrong?

Education & Training

Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 1998 - 1999
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1996 - 1998
Baylor College of MedicineResidency, Internal Medicine, 1993 - 1996
Medical University of Sofia FOMClass of 1987

Certifications & Licensure

NH State Medical License 1999 - 2025
MI State Medical License 1996 - 2000
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013

Clinical Trials

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Start of enrollment: 2000 Mar 01
Completed
Phase 1
Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer Start of enrollment: 2005 Aug 01
Completed
Phase 2
Study of Tarceva and Targretin in Stage I-II Lung Cancer Start of enrollment: 2005 Dec 01
Completed
Not Applicable
A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer Start of enrollment: 2009 Mar 01
Completed
Not Applicable
Pharmacokinetic & Pharmacodynamic Study of ABT-751 With Carboplatin in Patients With Advanced Lung Cancer Start of enrollment: 2004 Sep 01
Terminated
Phase 1, Phase 2
Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract Start of enrollment: 2003 Apr 01
Completed
Phase 1
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
Completed
Phase 2
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
Active, not recruiting
Phase 3
Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery Start of enrollment: 2014 Sep 01
Terminated
Phase 2
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) Start of enrollment: 2015 Jun 26
Completed
Phase 1, Phase 2
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer Start of enrollment: 2016 May 11
Completed
Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Start of enrollment: 2017 Mar 24
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

The beginning of the perioperative immunotherapy era in early-stage non-small cell lung cancer.
Riano, I., Dragnev, K., Phillips, J.> ;Translational Lung Cancer Research. 2023 Nov 30
1 citations
Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer.
Ivy Riano, Inas Abuali, Aditya Sharma, Jewelia Durant, Konstantin H Dragnev> ;Pharmaceuticals. 2023 Feb 3
6 citations
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
Landon C Brown, Jason Zhu, Kunal Desai, Emily Kinsey, Chester Kao, Yong Hee Lee, Sarabjot Pabla, Matthew K Labriola, Jennifer Tran, Konstantin H Dragnev, Laura J Tafe,...> ;Journal for Immunotherapy of Cancer. 2022 Oct 1
6 citations
Predicting oncogene mutations of lung cancer using deep learning and histopathologic features on whole-slide images.
Naofumi Tomita, Laura J Tafe, Arief A Suriawinata, Gregory J Tsongalis, Mustafa Nasir-Moin, Konstantin Dragnev, Saeed Hassanpour> ;Translational Oncology. 2022 Oct 1
62 citations
Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MA...
Karen L Reckamp, Mary W Redman, Konstantin H Dragnev, Katherine Minichiello, Liza C Villaruz, Bryan Faller, Tareq Al Baghdadi, Susan Hines, Leah Everhart, Louise Highl...> ;Journal of Clinical Oncology. 2022 Jul 20
3 citations
Prioritizing Measures That Matter Within a Person-Centered Oncology Learning Health System.
Aricca D Van Citters, Alice M Kennedy, Kathryn B Kirkland, Konstantin H Dragnev, Steven D Leach, Madge E Buus-Frank, Elissa F Malcolm, Megan M Holthoff, Anne B Holmes,...> ;JNCI Cancer Spectrum. 2022 May 2
Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients W...
Thomas A. Hensing, Xiaofei Wang, Thomas E. Stinchcombe, Junheng Gao, Michael V. Knopp, Mark A. Watson, Arkadiusz Z. Dudek, Stephen L. Graziano, Jyoti D. Patel, Bryan A...> ;JTO Clinical and Research Reports. 2021 Aug 1
14 citations
A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer.
Lauren Averett Byers, Alejandro Navarro, Eric Scott Schaefer, Melissa Lynne Johnson, Mustafa Ozguroglu, Ji-Youn Han, Igor Bondarenko, Irfan Cicin, Konstantin H. Dragne...> ;Clinical Lung Cancer. 2021 Apr 24
31 citations
Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results f...
Jared Weiss, Jerome H. Goldschmidt, Z. Andric, Konstantin H. Dragnev, Chad Gwaltney, Konstantina Skaltsa, Yili Pritchett, Joyce M Antal, Shannon R. Morris, Davey B. Da...> ;Clinical Lung Cancer. 2021 Mar 26
43 citations
Impact of the COVID-19 Pandemic on Oncologist Burnout, Emotional Well-Being, and Moral Distress: Considerations for the Cancer Organization's Response for Readiness, M...
Fay J. Hlubocky, Banu E. Symington, Daniel C. McFarland, Colleen M. Gallagher, Konstantin H. Dragnev, John M. Burke, Richard T. Lee, Areej El-Jawahri, Beth Popp, Abby ...> ;JCO Oncology Practice. 2021 Feb 8
32 citations
A randomized phase III study of abemaciclib versus erlotinib in patients with stage IV non-small cell lung cancer with a detectable KRAS mutation who failed prior plat...
Jonathan W. Goldman, Julien Mazieres, Fabrice Barlesi, Konstantin H. Dragnev, Marianna Koczywas, Tuncay Göskel, Alexis B. Cortot, Nicolas Girard, C. Wesseler, Helge Bi...> ;Frontiers in Oncology. 2020 Oct 26
41 citations
CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in pati...
Anne Y. Lai, Jessica A. Sorrentino, Konstantin H. Dragnev, Jared Weiss, Taofeek K. Owonikoko, Julie A. Rytlewski, Jill Hood, Zhao Yang, Rajesh K. Malik, Jay C. Strum, ...> ;Journal for Immunotherapy of Cancer. 2020 Oct 1
1 citations
Molecular matching and treatment strategies for advanced stage lung cancer at Dartmouth-Hitchcock Medical Center: A three-year review of a Molecular Tumor Board.
Erica B. Bernhardt, Mary D. Chamberlin, Ivan P. Gorlov, Francine B. de Abreu, Katarzyna Bloch, Jason D. Peterson, Gregory J. Tsongalis, Keisuke Shirai, Konstantin H. D...> ;Practical Laboratory Medicine. 2020 Jun 12
7 citations
Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients.
Tian Zhang, Sarabjot Pabla, Felicia L. Lenzo, Jeffrey M. Conroy, Mary Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Vincent Giamo, Jonathan Andre...> ;Oncoimmunology. 2020 Jun 10
3 citations
Impact of neuroimaging in the pretreatment evaluation of early stage non-small cell lung cancer.
Garrett Wasp, Christopher Del Prete, Jonathan A.D. Farrell, Konstantin H. Dragnev, Gregory A. Russo, Graham T. Atkins, Joseph D. Phillips, Gabriel A. Brooks> ;Heliyon. 2020 Jun 1
22 citations
Protein-altering germline mutations implicate novel genes related to lung cancer development.
Xuemei Ji, Semanti Mukherjee, Maria Teresa Landi, Yohan Bossé, Philippe Joubert, Dakai Zhu, Ivan P. Gorlov, Xiangjun Xiao, Younghun Han, Olga Y. Gorlova, Rayjean J. Hu...> ;Nature Communications. 2020 May 11
28 citations
A Call to Action: Ethics Committee Roundtable Recommendations for Addressing Burnout and Moral Distress in Oncology.
Fay J. Hlubocky, Lynne P Taylor, Jonathan M. Marron, Rebecca Spence, Molly M. McGinnis, Richard F. Brown, Daniel C. McFarland, Eric Daniel Tetzlaff, Colleen M. Gallagh...> ;JCO Oncology Practice. 2020 Mar 30
7 citations
Rapid EGFR mutation testing in lung cancer tissue samples using a fully automated system and single-use cartridge.
M. Rabie Al-Turkmani, Michael A. Suriawinata, Sophie J. Deharvengt, Donald Green, Candice C. Black, Keisuke Shirai, Konstantin H. Dragnev, Gregory J. Tsongalis> ;Practical Laboratory Medicine. 2020 Mar 2
5 citations
An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung c...
Muhammad Zubair Afzal, Konstantin H. Dragnev, Keisuke Shirai> ;Annals of Translational Medicine. 2019 Nov 3
91 citations
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.
Jared Weiss, Tibor Csoszi, M. Maglakelidze, Robert Hoyer, J.T. Beck, M. Domine Gomez, A. Lowczak, Raid Aljumaily, C.M. Rocha Lima, Ralph V. Boccia, Wahid Hanna, Petros...> ;Annals of Oncology. 2019 Oct 1
49 citations
Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors.
Muhammad Zubair Afzal, Konstantin H. Dragnev, Tayyaba Sarwar, Keisuke Shirai> ;Lung Cancer Management. 2019 May 7
7 citations
Small-cell lung cancer growth inhibition: synergism between NMDA receptor blockade and chemotherapy
William G. North, Fuli Liu, Konstantin H. Dragnev, Eugene Demidenko> ;Clinical Pharmacology. 2019 Jan 23
59 citations
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Journal for Immunotherapy of Cancer. 2019 Feb 1
63 citations
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
Jeffrey M. Conroy, Sarabjot Pabla, Mary Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jonathan Andreas, Vincent Giamo, Yirong Wang, Felicia L. Le...> ;Journal for Immunotherapy of Cancer. 2019 Jan 24
4 citations
Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Nonsquamous, Non–Small Cell Lung Cancer
Gabriel A. Brooks, Andrea M. Austin, Hajime Uno, Konstantin H. Dragnev, Anna N. A. Tosteson, Deborah Schrag> ;JAMA Network Open. 2018 Oct 5
Join now to see all

Press Mentions

SWOG S2302 Pragmatica-Lung Study Opens to Enrollment, a Model for Easier, More Representative Clinical TrialsApril 12th, 2023
New Drug Combination Lengthened Survival for Some with Lung CancerJune 3rd, 2022
Lung-MAP: A Five-Year Recap on the First Master Protocol Trial in Cancer ResearchFebruary 21st, 2020
Join now to see all